Kiniksa Pharmaceuticals International vs PACS Group

Kiniksa Pharmaceuticals International (KNSA), health care, and PACS Group (PACS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

PACS Group is worth $7.7B on the stock market and Kiniksa Pharmaceuticals International $7.5B: PACS Group is valued at 3% more. Kiniksa Pharmaceuticals International trades at 71.5 times earnings and PACS Group at 27.9; operating margins in their latest fiscal years were 11.4% and 5.85%. Over the past year Kiniksa Pharmaceuticals International's share price has moved +128% and PACS Group's +240%.

Key facts

Kiniksa Pharmaceuticals International market value
$7.5B
PACS Group market value
$7.7B
Kiniksa Pharmaceuticals International P/E
71.5
PACS Group P/E
27.9
Kiniksa Pharmaceuticals International revenue
$677.6MFY to 2025-12-31
PACS Group revenue
$5.3BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Kiniksa Pharmaceuticals International vs PACS Group: every measure side by side
Measure Kiniksa Pharmaceuticals International PACS Group
SectorHealth CareHealth Care
Country United Kingdom United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.5Blower$7.7Bhigher
Revenue$677.6Mlower$5.3Bhigher
Earnings$59Mlower$191.5Mhigher
Employees366lower47,455higher
Total assets$763.6Mlower$5.6Bhigher
Valuation
P/E71.5higher27.9lower
P/S11.0higher1.5lower
P/B—6.3
Dividend yield—0.00%
Profitability
Operating margin11.4%higher5.85%lower
Balance sheet
Net assets$567.6Mlower$946.8Mhigher
Total liabilities$196Mlower$4.6Bhigher
Total debt—$353.2M
Cash on hand$165.6Mlower$197Mhigher
Price change
Today+0.93%higher-0.92%lower
1 year+128%lower+240%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Kiniksa Pharmaceuticals International only (1)

PACS Group only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns KNSA · Who owns PACS

Further comparisons

Learn

Questions and answers

Which is bigger, Kiniksa Pharmaceuticals International or PACS Group?

By market value, PACS Group is the larger: $7.7B against $7.5B for Kiniksa Pharmaceuticals International. By revenue in its latest fiscal year, PACS Group is the larger: $5.3B against $677.6M for Kiniksa Pharmaceuticals International.

Which has the higher P/E ratio?

Kiniksa Pharmaceuticals International: 71.5, against 27.9 for PACS Group. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Kiniksa Pharmaceuticals International: 11.4%, against 5.85% for PACS Group. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Kiniksa Pharmaceuticals International and PACS Group?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Kiniksa Pharmaceuticals International and 1 holds PACS Group.

Cite this page

Funkfolio, “Kiniksa Pharmaceuticals International vs PACS Group”, data as of 18 November 2026. https://funkfolio.com/compare/knsa-vs-pacs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.